

RECEIVED
CENTRAL FAX CENTER

IMPORTANT CONFIDENTIALITY NOTICE

OCT 24 2007

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

TO: Amendment - United States Patent and Trademark Office

Fax No. 571-273-8300

FROM: Sandy Wilson

The Procter & Gamble Company


Fax No. 513-634-3752

Phone No. 513-634-4223

Application No. : 10/758,997
Inventor(s) : Michael Nyle Hershberger
Filed : Jan. 16, 2004
Docket No. : P155
Confirmation No. : 1645

FACSIMILE TRANSMITTAL SHEET AND**CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on Oct. 24, 2007, to the above-identified facsimile number.

 (Signature)

Listed below are the item(s) being submitted with this Certificate of Transmission:**

- 1) Supplemental Information Disclosure Statement 2 pages
- 2) PTO/SB08A 1 page
- 3)

Comments:

****Note:** Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper. (FAX-USPTO.doc Revised 11/18/2005)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
OCT 24 2007

Application No. : 10/758,997
Inventor(s) : Michael Nyle Hershberger
Filed : Jan. 16, 2004
Art Unit : 1645
Examiner : Nathan W. Schlientz
Docket No. : P 155
Confirmation No. : 1645
Customer No. : 27752
Title : Liquid Compositions Comprising One or More
Medicaments

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, it is respectfully requested that the document(s) cited in this submission be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the document(s) cited in this submission is (are), or is (are) considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

This Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Authorization is hereby given to charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company.

Appl. No. 10/758,997
Docket No. P155
Customer No. 27752

2

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Sarah Ann Dressel

Typed or printed name

Registration No. 58,484

(513) 634-1452

Date: Oct. 24, 2007
Customer No. 27752
(IDS.doc) (Last Revised 07/27/2007)